HomeCompareMTHRY vs ARCC

MTHRY vs ARCC: Dividend Comparison 2026

MTHRY yields 0.97% · ARCC yields 10.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MTHRY wins by $4.15M in total portfolio value· pulled ahead in Year 4
10 years
MTHRY
MTHRY
● Live price
0.97%
Share price
$5.08
Annual div
$0.05
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.17M
Annual income
$3,485,360.67
Full MTHRY calculator →
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — MTHRY vs ARCC

📍 MTHRY pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMTHRYARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MTHRY + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MTHRY pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MTHRY
Annual income on $10K today (after 15% tax)
$82.73/yr
After 10yr DRIP, annual income (after tax)
$2,962,556.57/yr
ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, MTHRY beats the other by $2,962,555.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MTHRY + ARCC for your $10,000?

MTHRY: 50%ARCC: 50%
100% ARCC50/50100% MTHRY
Portfolio after 10yr
$2.10M
Annual income
$1,742,680.91/yr
Blended yield
83.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

MTHRY
No analyst data
Altman Z
5.3
Piotroski
4/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MTHRY buys
0
ARCC buys
0
No recent congressional trades found for MTHRY or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMTHRYARCC
Forward yield0.97%10.82%
Annual dividend / share$0.05$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%-50%
Portfolio after 10y$4.17M$24.5K
Annual income after 10y$3,485,360.67$1.16
Total dividends collected$4.09M$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: MTHRY vs ARCC ($10,000, DRIP)

YearMTHRY PortfolioMTHRY Income/yrARCC PortfolioARCC Income/yrGap
1$10,895$194.65$11,381$541.15$486.00ARCC
2$12,054$396.38$12,621$284.08$567.00ARCC
3$13,717$819.72$13,827$145.31$110.00ARCC
4← crossover$16,421$1,743.63$15,062$73.43+$1.4KMTHRY
5$21,472$3,901.55$16,364$36.89+$5.1KMTHRY
6$32,511$9,535.79$17,757$18.49+$14.8KMTHRY
7$61,774$26,987.25$19,258$9.25+$42.5KMTHRY
8$161,946$95,847.66$20,880$4.63+$141.1KMTHRY
9$642,952$469,669.69$22,636$2.32+$620.3KMTHRY
10$4,173,319$3,485,360.67$24,539$1.16+$4.15MMTHRY

MTHRY vs ARCC: Complete Analysis 2026

MTHRYStock

M3, Inc. provides medical-related services primarily to physicians and other healthcare professionals through Internet. The company operates through five reporting segments: Medical Platform, Evidence Solution, Career Solution, Site Solution, and Overseas. It operates m3.com, a members-only Web site for providing information to the healthcare professionals; MR-kun, where member doctors can independently and continuously receive information on the m3com platform; QOL-kun that provides life support information other than medical information to members; AskDoctors, where registered doctors answer questions about health and illness from the general public; MDLinx for medical professionals in the United States; and Doctorsnetuk, a website that provides developing services for pharmaceutical companies, as well as provides drug information database in France, Germany, and Spain. The company also provides career services for doctors and pharmacists through m3com CAREER. In addition, it engages in the sales activities and marketing operations for pharmaceuticals and medical devices; development, sale, and support business of electronic medical records and medical equipment for medical institutions; survey service for medical professionals; sale and marketing support businesses for pharmaceutical companies, etc. through the Internet; provision of management support and consulting services to medical institutions, and home-visit nursing services; and provision of human resources services for healthcare professionals, as well as operates clinical trial facilities. The company was formerly known as So-netM3, Inc. and changed its name to M3, Inc. in January 2010. M3, Inc. was incorporated in 2000 and is headquartered in Tokyo, Japan.

Full MTHRY Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this MTHRY vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MTHRY vs SCHDMTHRY vs JEPIMTHRY vs OMTHRY vs KOMTHRY vs MAINMTHRY vs HTGCMTHRY vs GBDCMTHRY vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.